Protalix BioTherapeutics, a biopharmaceutical company specializing in rare disease treatments, will release its financial results for Q2 2026 on August 12. The company will also provide a business update and discuss recent corporate and regulatory developments during a conference call and webcast at 8:00 a.m. EDT. Protalix is known for its innovative plant cell-based protein production system and has partnerships with Pfizer and Chiesi for its enzyme replacement therapies. Investors can access the live call via phone or webcast, with a replay available for two weeks afterward.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Kuehn Law is investigating Picard Medical Inc. for possible breaches of fiduciary duty by its officers and directors. The lawsuit alleges that insiders engaged in a fraudulent stock promotion scheme using social media misinformation and fake financia...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Listen Labs, a startup using voice AI for customer interviews, walked away from a signed $125 million Series C funding round led by Menlo Ventures. The funding likely fell through due to ongoing acquisition talks with Salesforce, which is considering...
